For Prelims: National Pharmaceutical Pricing Authority (NPPA), Maximum Retail Price (MRP), Trade Margin Capping, Directorate General of Health Services (DGHS), Nodal Body, Parent Ministry, Annual Savings for Consumers, Number of Drugs with Capped Margins
For Mains: Trade margin capping, affordable cancer care, regulatory intervention, consumer protection, DPCO 2013, NPPA
Source:
The Hindu
5 facts for one-day exams
SSC, railway, police and teaching exams ask direct questions like these.
- NPPA capped trade margins on 137 anti-cancer drugs.
- Revised MRPs for 1,364 formulations came into effect on November 9, 2026.
- Annual savings for consumers: ₹3,540 crore.
- Highest price cut recorded: 96.45%.
- NPPA is under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
Why in the news?
The National Pharmaceutical Pricing Authority (NPPA) has capped trade margins on 137 anti-cancer drugs, leading to revised MRPs for 1,364 formulations. Consumers are expected to save ₹3,540 crore annually, with price cuts of over 50% for 679 brands and a maximum reduction of 96.45%.
Summary
- NPPA capped trade margins on 137 anti-cancer drugs based on an Expert Committee recommendation from the DGHS, Ministry of Health & Family Welfare.
- 85 pharmaceutical companies reported revised MRPs for 1,364 formulations across 121 drugs as of November 8, 2026.
- Price reductions over 50% were reported for 679 brands; the highest single price cut was 96.45%.
- Consumers can verify prices via the 'Pharma Sahi Daam' app, NPPA website, or lodge complaints on the Pharma Jan Samadhan portal or helpline 1800-111-255.
Highlights
Trade Margin Capping on 137 Anti-Cancer Drugs
NPPA capped trade margins on 137 anti-cancer drugs, forcing revised MRPs on 1,364 formulations across 121 drugs.
₹3,540 Crore Annual Savings for Patients
The move is projected to save consumers an estimated ₹3,540.38 crore annually, with 679 brands seeing price cuts over 50%.
Consumer Verification and Grievance Channels
Patients can check revised MRPs via the 'Pharma Sahi Daam' app or NPPA website, and report overcharging on the Pharma Jan Samadhan portal or helpline 1800-111-255.
Background
Cancer treatment in India has historically been expensive due to high trade margins on drugs, making them unaffordable for many patients. The NPPA, under the Department of Pharmaceuticals (Ministry of Chemicals and Fertilizers), has the mandate to regulate drug prices under the Drugs (Prices Control) Order, 2013. An Expert Committee constituted by the DGHS (Ministry of Health & Family Welfare) submitted recommendations on October 17, 2026, to cap trade margins on 137 anti-cancer drugs, leading to this price revision.
Key Analysis and Impact
The price revision covers 1,364 formulations from 85 companies across 121 drugs. The highest price cut of 96.45% and over 50% reductions for 679 brands indicate a significant intervention to make cancer care more affordable. The annual savings of ₹3,540 crore directly reduce the financial burden on patients and their families. The move also strengthens the regulatory framework by mandating that no chemist or hospital pharmacy can charge above the revised MRP, with multiple channels for consumer verification and grievance redressal (Pharma Sahi Daam app, Pharma Jan Samadhan portal, helpline).
Way Forward
The success of this initiative depends on strict enforcement and awareness among patients and chemists. The NPPA may extend trade margin capping to other critical disease categories (e.g., cardiac, rare diseases). Regular monitoring through the Pharma Jan Samadhan portal will help identify violations. Future policy could focus on further reducing the cost of cancer care through bulk procurement, generic promotion, and strengthening the public health system's cancer treatment infrastructure.
Background GK
Textbook concepts you need to understand this news
- National Pharmaceutical Pricing Authority (NPPA)
- An autonomous regulatory body under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, established in 1997 to fix and revise prices of controlled bulk drugs and formulations, and to enforce the Drugs (Prices Control) Order.
- Maximum Retail Price (MRP)
- The highest price at which a product can be sold to the end consumer in India. It includes all taxes and distribution costs; retailers cannot charge more than the printed MRP.
- Trade Margin Capping
- A regulatory mechanism where the government fixes the maximum profit margin (trade margin) that manufacturers, distributors, and retailers can add to the cost of a drug, to prevent overpricing and ensure affordability.
- Directorate General of Health Services (DGHS)
- An attached office of the Ministry of Health and Family Welfare, responsible for technical aspects of healthcare delivery, including disease control, medical education, and public health standards.
Facts to remember
Tap a card to see the answer. Try to recall it first.
How exams will ask this
- Data: ₹3,540.38 crore annual savings; 1,364 formulations; 137 drugs; 96.45% highest price cut; 679 brands with >50% cut.
- Nodal Body: National Pharmaceutical Pricing Authority (NPPA) under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
- Legal Point: Drugs (Prices Control) Order, 2013 (DPCO, 2013) under which NPPA operates.
Don't make this mistake!
Students may confuse NPPA with the National Pharmaceutical Pricing Authority under the Ministry of Health. It is actually under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. Also, this is trade margin capping, not a direct price control on all drugs — only on 137 specific anti-cancer drugs. The savings are projected annual savings, not actual achieved savings.
Write these in mains answers
- Trade margin capping, affordable cancer care, regulatory intervention, consumer protection, DPCO 2013, NPPA
Stuck? Get it in one tap
The government's drug price regulator, NPPA, has capped the profit margins that companies and pharmacies can add to 137 cancer drugs. This has forced companies to reduce the maximum retail price (MRP) of over 1,300 medicine variants. The biggest single price cut is 96.45%, meaning a drug that cost ₹100 now costs less than ₹4. Patients can check the new price on a government app or website and report any shop that overcharges them.
- NPPA capped trade margins on 137 anti-cancer drugs.
- Revised MRPs for 1,364 formulations came into effect on November 9, 2026.
- Annual savings for consumers: ₹3,540 crore.
- Highest price cut recorded: 96.45%.
- NPPA is under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
- Economy: Government intervention in markets and price regulation
- Governance: Regulatory bodies and consumer protection
Related concepts: National Pharmaceutical Pricing Authority (NPPA), Maximum Retail Price (MRP), Trade Margin Capping, Directorate General of Health Services (DGHS)
Practice questions
Pick an answer, then read the explanation.
- Q1Easy
The National Pharmaceutical Pricing Authority (NPPA) functions under which ministry?
Explanation: NPPA is under the Department of Pharmaceuticals, which is a department of the Ministry of Chemicals and Fertilizers. It is not under the Ministry of Health and Family Welfare, even though it regulates drug prices. The Ministry of Finance and Ministry of Commerce and Industry are not involved in drug pricing regulation.
- Q2Hard
Consider the following statements regarding the recent revision of MRPs of anti-cancer formulations:
- 1.The revision was based on recommendations from an Expert Committee constituted by the Ministry of Chemicals and Fertilizers.
- 2.The revised MRPs came into effect from November 9, 2026.
- 3.Consumers can verify revised MRPs through the 'Pharma Sahi Daam' mobile application.
Which of the statements given above is/are correct?
Explanation: Statement 1 is incorrect because the Expert Committee was constituted by the Directorate General of Health Services (DGHS), Ministry of Health & Family Welfare, not by the Ministry of Chemicals and Fertilizers. Statement 2 is correct: the revised MRPs came into effect from Monday, November 9, 2026. Statement 3 is correct: consumers can verify medicine rates via the 'Pharma Sahi Daam' mobile application.
- Q3Medium
What is the estimated annual savings for consumers from the revised MRPs of anti-cancer formulations?
Explanation: The official release projects annual savings of ₹3,540.38 crore for consumers. ₹2,540 crore is too low, ₹4,540 crore and ₹5,540 crore are higher than the actual figure. The precise number to remember for exams is ₹3,540 crore (approximately).
- Q4Medium
What is the primary objective of NPPA capping trade margins on anti-cancer drugs?
Explanation: The primary objective of trade margin capping is to reduce the financial burden on cancer patients by lowering the retail price of drugs. It is not aimed at increasing government revenue, reducing the number of formulations, or promoting exports. The projected savings of ₹3,540 crore directly benefit consumers.
Frequently asked questions
1. What is the NPPA's recent move regarding anti-cancer drugs?
The NPPA capped trade margins on 137 anti-cancer drugs, leading to revised MRPs for 1,364 formulations, effective from November 9, 2026.
2. How much money will consumers save annually from this price revision?
Consumers are projected to save an estimated ₹3,540.38 crore annually due to the revised MRPs.
3. How can patients verify the revised MRP of their medicines?
Patients can check the revised MRP printed on the pack, use the 'Pharma Sahi Daam' mobile app, or visit the official NPPA website.
4. Where can consumers complain about overcharging for cancer drugs?
Consumers can lodge complaints on the Pharma Jan Samadhan portal or call the NPPA helpline at 1800-111-255.
All sources
- Original9 November 2026 · Read story
